Clinical trial
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors…
NCT00004075 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00004075 |
|---|---|
| Title | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery |
| Official title | A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) in Solid Tumor and Lymphoma Patients |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Start date | Aug 1, 1999 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 3, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: